Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ADXS PSA

Next Previous
Search
Drug Profile

ADXS PSA

Alternative Names: ADXS-PSA; ADXS31-142; Live attenuated Listeria-based vaccines for cancer - Ayala Pharmaceuticals; Lovaxin P; Prostate cancer vaccine - Ayala Pharmaceuticals

Latest Information Update: 23 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advaxis
  • Developer Ayala Pharmaceuticals; Merck & Co
  • Class Cancer vaccines; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; Neoplasm protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 19 Jan 2023 Advaxis has merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals
  • 08 Oct 2021 Phase I/II trial is still ongoing for Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (NCT02325557)
  • 08 Oct 2021 Phase I/II trial is still ongoing for Prostate cancer (Hormone refractory, Metastatic disease, Monotherapy) in USA (NCT02325557)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top